重大事件
即時報告
8-K
2026-06-22
BridgeBio Oncology Therapeutics 年會完成董事選舉及續聘核數師 股東支持度普遍高
AI 繁中摘要
📋 **SEC 8-K 申報摘要**
**公司：BridgeBio Oncology Therapeutics, Inc.（代碼：BBOT）**
**申報日期：2026年6月22日（事件發生日期：2026年6月16日）**
---
### 1️⃣ 董事辭任（Item 5.02）
董事 Michelle Doig 於2026年6月16日完成其第I類董事任期後正式辭任，即日生效。辭任原因並非與公司營運、政策或實務有任何分歧，屬正常任期屆滿交接。
---
### 2️⃣ 2026年股東週年大會投票結果（Item 5.07）
大會於2026年6月16日舉行，合共80,112,725股有投票權，出席（含委託書）48,344,441股，約佔60.4%。
#### 📌 提案一：選舉兩名第I類董事（任期至2029年年會）
- **Peter Lebowitz, M.D., Ph.D.**：贊成 31,822,504 票 / withheld 3,372 票
- **Frank P. McCormick, Ph.D., F.R.S., D. Sc.**：贊成 25,654,119 票 / withheld 6,171,757 票
- 經紀人非投票 2,713,439 票，反對 13,805,126 票（實際為「不投票」選項）
👉 兩人均成功當選，但 McCormick 的 withheld 票數較高，反映部分股東可能有保留意見。
#### 📌 提案二：批准聘任核數師
批准續聘 Deloitte & Touche LLP 為2026年度（截至12月31日）獨立註冊會計師事務所。
- 贊成 34,535,875 票 / 反對 3,440 票 / 棄權 0 票
- 無經紀人非投票，反對票極少，顯示股東普遍支持。
---
### 🔍 對投資者的潛在影響
- **董事會變動**：Doig 離任屬計劃內交接，短期對管治影響有限；惟 McCormick 獲 withheld 票數較多，投資者可留意未來董事會溝通或問責情況。
- **會計師事務所續聘獲壓倒性支持**，減低審計相關不確定性。
- 整體而言，此次8-K屬例行企業管治更新，未見重大突發事件或營運變動，市場反應料平穩。
✔️ 總結：公司順利完成年會各項議案，董事會輕微重組，審計安排持續穩定。
展開英文正文
8-K false 0001869105 0001869105 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2026 BridgeBio Oncology Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41955 39-3690783 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 256 E. Grand Avenue, Suite 104 South San Francisco, CA 94080 (Address of principal executive offices, including zip code) (650) 405-4770 (Telephone number, including area code, of agent for service) (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share BBOT The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 16, 2026, Michelle Doig notified BridgeBio Oncology Therapeutics, Inc. (the “Company”), of her resignation as a member of the Board of Directors of the Company (the “Board”) upon the completion of her term as a Class I director, effective as of June 16, 2026, the date of the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Ms. Doig’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Item 5.07. Submission of Matters to a Vote of Security Holders. The proposals set forth below were submitted to the stockholders at the Annual Meeting held on June 16, 2026, with each such proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2026 (the “Proxy Statement”). The number of shares of common stock entitled to vote at the Annual Meeting was 80,112,725. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 48,344,441. The number of votes cast for and against and the number of abstentions, broker non-votes and no votes with respect to each proposal voted upon are set forth below. Proposal 1 - Election of Directors. The Company’s stockholders elected the two (2) director nominees below to the Company’s Board of Directors as Class I directors to hold office until the 2029 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified. Director Nominee Votes For Votes Withheld Peter Lebowitz, M.D., Ph.D. 31,822,504 3,372 Frank P. McCormick, Ph.D., F.R.S., D. Sc. 25,654,119 6,171,757 There were 2,713,439 broker non-votes and 13,805,126 no votes regarding this proposal. Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm. The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. Votes For Votes Against Abstentions 34,535,875 3,440 0 There were zero broker non-votes and 13,805,126 no votes regarding this proposal. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. Date: June 22, 2026 By: /s/ Pedro J. Beltran, Ph.D. Name: Pedro J. Beltran, Ph.D. Title: Chief Executive Officer